Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,849 | 726 | 5,061 |
| Samples | 1,925 | 321 | 1,582 |
| Peptides | 1,696 | 238 | 1,482 |
Function
NAV3 · Neuron navigator 3
This gene belongs to the neuron navigator family and is expressed predominantly in the nervous system. The encoded protein contains coiled-coil domains and a conserved AAA domain characteristic for ATPases associated with a variety of cellular activities. This gene is similar to unc-53, a Caenorhabditis elegans gene involved in axon guidance. Multiple alternatively spliced transcript variants for this gene have been described but only one has had its full-length nature determined. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000397909 | Q8IVL0 | 2,277 | 1,621 |
| ENST00000536525 | Q8IVL0-2 | 2,071 | 1,562 |
| ENST00000644176 | A0A2R8YFX5* | 1,499 | 1,122 |
| ENST00000549464 | F8VZV4* | 1 | 1 |
| ENST00000550042 | A0A1B0GTC4* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 1621 amino-acid changes on canonical ENST00000397909 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NAV3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NAV3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 7/25 28% | 0/0 0% |
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 12/57 21% | 135/810 17% |
| Non-Small Cell Lung Carcinoma | 78/304 26% | 187/1390 13% |
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 59/612 10% |
| Small Cell Lung Carcinoma | 2/9 22% | 75/752 10% |
| Melanoma | 13/210 6% | 136/1899 7% |
| Gastric Carcinoma | 8/74 11% | 120/1809 7% |
| Other Solid Cancers | 4/94 4% | 99/1515 7% |
| Cervical Carcinoma | 4/35 11% | 25/422 6% |
| Colorectal Carcinoma | 36/143 25% | 160/3239 5% |
| Neuroendocrine Tumour | 32/154 21% | 10/577 2% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Esophageal Carcinoma | 1/23 4% | 38/769 5% |
| Bladder Carcinoma | 0/58 0% | 43/956 4% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 105/2550 4% |
| Head and Neck Carcinoma | 10/85 12% | 58/1574 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Plasma Cell Myeloma | 6/44 14% | 5/305 2% |
| Hepatocellular Carcinoma | 3/46 7% | 57/2210 3% |
| Other Sarcomas | 5/69 7% | 15/699 2% |
| Germ Cell Tumour | 0/25 0% | 5/169 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Biliary Tract Carcinoma | 0/54 0% | 19/950 2% |
| Ovarian Carcinoma | 6/109 6% | 14/998 1% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
Mutation Distribution
Where NAV3 is mutated · all tissues, split by cell line vs tissue
How many mutations in NAV3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,849 mutations in NAV3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|